From the Wires
Ghent University and MDxHealth Collaborate to Establish a Center in Pharmaco (Epi)genomics
By: Marketwired .
Nov. 30, 2012 02:44 AM
IRVINE, CA, and LIEGE, BELGIUM -- (Marketwire) -- 11/30/12 -- MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced that it has joined forces with the Ghent University to establish NXTGNT, a new Center in Pharmaco (Epi)genomics.
The mission of the Center is to accelerate innovation in personalized medicine by using advanced technology, knowledge and expertise in (epi)genetics. The Center will bring together scientific expertise from disease centered basic researchers, corresponding clinical validation teams, bioinformaticians, and cutting edge (epi)genomic technology focused on the discovery of effective individualized epigenetic-based diagnostic and personalized therapeutic products.
As a result of several years of productive collaboration between the Laboratory of Bioinformatics and Computational Genomics (BIOBIX), NXTGNT (UGent genome analysis facility), the Biomarked valorization consortium teams and MDxHealth, the new Center is located at Ghent University within the laboratory of Pharmaceutical Biotechnology. The facility will house MDxHealth's research team and lab equipment for development of epigenetic tests together with the Ghent University team for (epi)genetic sequencing. The facility works in close collaboration with the Laboratory of Bioinformatics and Computational Genomics, located at the Faculty of BioEngeneering, providing extensive expertise in epigenetic characterization and computing and visualization of (epi)genomic datasets. The Center is fully operational as off December 1, 2012.
"The creation of NXTGNT as a Center in Pharmaco (Epi)genomics is welcome advancement in the field of epigenetics and personalized medicine. There is a history of successful collaboration between MDxHealth and the University of Ghent, where much of the early epigenetics sequencing work on our biomarkers was conducted," said Dr. Jan Groen CEO of MDxHealth. "As more drugs are being developed alongside companion tests, there is a growing need for novel technologies, biomarkers and assays. We believe our experience in successfully developing personalized cancer epigenetic tests combined with the sequencing, bioinformatics and methylome analysis expertise contained in the new Center will prove extremely attractive to the pharmaceutical industry."
"The partners in NXTGNT and the University of Ghent have an established track record in biomarker research. Performing research towards technological advances, identification and validation of novel and more accurate biomarkers for risk stratification and prediction of therapy and our expertise in data-analysis and the development of new bioinformatic tools are an asset in this collaboration," Said Prof. Dieter Deforce from the University of Ghent, one of the NXTGNT partners. "By collaborating with MDxHealth we will ensure that results from our research in the collaboration field will be brought to the market in a more efficient way. Bringing the right partners together with the necessary contacts in the pharmaceutical industry will allow us to further advance in the field of personalized medicine."
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.
For more information:
Latest Cloud Developer Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week